Autolus Therapeutics (AUTL) Competitors $3.08 +0.07 (+2.33%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends AUTL vs. APLS, MRUS, IBRX, MLTX, BHC, AGIO, XENE, PTCT, EWTX, and HCMShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Apellis Pharmaceuticals (APLS), Merus (MRUS), ImmunityBio (IBRX), MoonLake Immunotherapeutics (MLTX), Bausch Health Companies (BHC), Agios Pharmaceuticals (AGIO), Xenon Pharmaceuticals (XENE), PTC Therapeutics (PTCT), Edgewise Therapeutics (EWTX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Apellis Pharmaceuticals Merus ImmunityBio MoonLake Immunotherapeutics Bausch Health Companies Agios Pharmaceuticals Xenon Pharmaceuticals PTC Therapeutics Edgewise Therapeutics HUTCHMED Autolus Therapeutics (NASDAQ:AUTL) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Does the MarketBeat Community believe in AUTL or APLS? Apellis Pharmaceuticals received 119 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 67.67% of users gave Autolus Therapeutics an outperform vote while only 67.65% of users gave Apellis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAutolus TherapeuticsOutperform Votes22467.67% Underperform Votes10732.33% Apellis PharmaceuticalsOutperform Votes34367.65% Underperform Votes16432.35% Do insiders & institutionals have more ownership in AUTL or APLS? 72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is AUTL or APLS more profitable? Autolus Therapeutics has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -34.97%. Autolus Therapeutics' return on equity of -63.65% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -63.65% -36.54% Apellis Pharmaceuticals -34.97%-103.11%-28.96% Do analysts recommend AUTL or APLS? Autolus Therapeutics presently has a consensus price target of $9.45, indicating a potential upside of 206.82%. Apellis Pharmaceuticals has a consensus price target of $51.06, indicating a potential upside of 94.36%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Apellis Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.79 Which has higher earnings & valuation, AUTL or APLS? Autolus Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$1.70M482.09-$208.38M-$1.21-2.55Apellis Pharmaceuticals$396.59M8.24-$528.63M-$2.03-12.94 Which has more volatility & risk, AUTL or APLS? Autolus Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Does the media favor AUTL or APLS? In the previous week, Autolus Therapeutics had 13 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 23 mentions for Autolus Therapeutics and 10 mentions for Apellis Pharmaceuticals. Autolus Therapeutics' average media sentiment score of 0.34 beat Apellis Pharmaceuticals' score of -0.28 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apellis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAutolus Therapeutics beats Apellis Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$819.56M$2.91B$5.06B$8.67BDividend YieldN/A1.79%5.06%4.06%P/E Ratio-2.5541.06100.7117.26Price / Sales482.09217.681,206.6171.28Price / CashN/A178.0140.7536.36Price / Book1.724.096.325.87Net Income-$208.38M-$42.42M$119.47M$225.66M7 Day Performance-17.43%-10.63%-5.11%-1.34%1 Month Performance-31.71%-6.02%-3.21%1.00%1 Year Performance-29.20%26.36%32.43%25.27% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics3.4408 of 5 stars$3.08+2.3%$9.45+206.8%-29.2%$819.56M$1.70M-2.55330Earnings ReportAnalyst UpgradeShort Interest ↓Analyst RevisionNews CoverageGap UpAPLSApellis Pharmaceuticals4.4976 of 5 stars$26.27-6.4%N/A-45.1%$3.27B$396.59M-12.94702High Trading VolumeMRUSMerus1.88 of 5 stars$46.58-6.2%N/A+95.7%$3.19B$43.95M-11.7937Positive NewsIBRXImmunityBio0.6999 of 5 stars$4.49-7.8%N/A+9.8%$3.13B$1.31M-4.88590MLTXMoonLake Immunotherapeutics3.332 of 5 stars$48.83-7.0%N/A+21.2%$3.12BN/A-37.852Analyst ForecastNews CoverageBHCBausch Health Companies2.7399 of 5 stars$8.48-3.2%N/A+29.3%$3.12B$8.76B-17.6720,270AGIOAgios Pharmaceuticals3.2918 of 5 stars$53.78-2.9%N/A+141.8%$3.07B$26.82M4.73390Short Interest ↑XENEXenon Pharmaceuticals3.7106 of 5 stars$39.83-4.6%N/A+38.8%$3.04B$9.43M-14.12251Earnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionNews CoveragePTCTPTC Therapeutics2.7835 of 5 stars$39.23-7.4%N/A+96.2%$3.03B$937.82M-6.601,410News CoverageEWTXEdgewise Therapeutics1.9077 of 5 stars$31.44-4.4%N/A+395.1%$2.98BN/A-20.9660Short Interest ↓Analyst RevisionNews CoveragePositive NewsHCMHUTCHMED1.5665 of 5 stars$16.74-0.7%N/A-4.7%$2.92B$838M0.001,988Short Interest ↓Positive News Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Merus Competitors ImmunityBio Competitors MoonLake Immunotherapeutics Competitors Bausch Health Companies Competitors Agios Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors PTC Therapeutics Competitors Edgewise Therapeutics Competitors HUTCHMED Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AUTL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUTL Stock Alerts